Low Dose Atropine for Symptomatic Vitreous Floaters

Jeanette Du200 enrolled

Overview

The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

200

Conditions

Vitreous Floaters

Interventions

0.01% atropine ophthalmic dropDRUG

0.01% atropine ophthalmic drop will be applied daily to the affected eye

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients within Prism Vision Group with ICD diagnosis of acute posterior vitreous detachment and none of the ocular comorbidities listed as exclusion criteria will be screened as potential study participants. Exclusion Criteria: * Patients with vitreous hemorrhage, other significant media opacity or vitreoretinal pathology, or history of pars plana vitrectomy will be excluded.

Locations (1)

Retina Group of Washington

Reston, Virginia, United States

Outcomes

Primary Outcomes

Symptom improvement assessed by questionnaire

NEI VFQ-25 = National Eye Institute Visual Function Questionnaire

Time frame: Up to 2 months

Central Contacts

Jeanette Du, MD

CONTACT

844-749-3627 JDu@rgw.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.